-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of March 30, WuXi Biologics (02269) issued an announcement stating that the company plans to cooperate with Shanghai Hequan Pharmaceutical Co.
According to the announcement, WuXi XDC will be engaged in the contract development and production of antibody-conjugated drugs (ADC) and other bio-conjugated drugs.
According to the announcement, WuXi Biologics and Hequan Pharmaceuticals will strive to build WuXi XDC into an integrated and end-to-end contract development and production service (CDMO) company, specializing in the development and production of ADCs and other bioconjugate drugs.